Skip to main content

Life Sciences is now live. See how →

Patent Examiner Karl J. Puttlitz

Art Unit 1646 · Immunology, Antibodies & Bio-Affecting Compositions · Tech Center 1600 · 303 applications filed 2021–2026

⚑ Hard · harder than 76% of examiners● Free examiner data

Karl J. Puttlitz is a USPTO patent examiner in Art Unit 1646 (Immunology, Antibodies & Bio-Affecting Compositions) with 303 applications from filing years 2021–2026. Examiner Puttlitz's allowance rate is 67.7%, below the 82.4% USPTO average for applications filed in the same years. The examiner ranks harder than 76% of examiners. In 2021, decided applications with an examiner interview were allowed 48.3 percentage points more often than those without.

Draft a response to Examiner PuttlitzSee the strategy data ↓

Data through October 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 76% of examiners
Easier76th percentileHarder
Allowance rate vs peers
Examiner Puttlitz67.7%
Art Units 1642 and 164659.9%
USPTO average82.4%
Allowance rate
67.7%
▼ USPTO avg 82.4%
Applications
303
filing years 2021–2026
First-action allowance
16.4%
patented with no rejection
Abandoned
20.1%
share of applications
Avg office actions
1.3
USPTO avg 1.3
Days to first OA
782
▲ USPTO 614
RCE rate
18.5%
USPTO 20.0%
Interview rate
30.0%
USPTO 27.7%

Examiner details

  • Art unit1646 · Immunology, Antibodies & Bio-Affecting Compositions
  • Title / gradePrimary Patent Examiner · GS-14
  • Service23 years
  • Phone(571) 272-0645
  • Email[email protected]
  • LocationAlexandria, VA 22314
  • In USPTO recordsPUTTLITZ, KARL J
Full signatory authority

Examiner Puttlitz can allow an application without a supervisory sign-off.

Examines (USPC classes)
424 · Drug, Bio-Affecting & Body Treating Compositions514 · Drug, Bio-Affecting & Body Treating Compositions530 · Chemistry: Natural Resins, Peptides or Proteins & Lignins

How to improve your odds with Examiner Puttlitz

  • The data favors an interview. Interviewed cases were allowed more often in all 4 measured years, by 16.7 to 50.0 points.
  • Plan for the timeline. First office action averages 782 days vs the 614-day USPTO norm.
  • Expect a §103. Obviousness is the most-issued rejection (169), and applicants overcame it 55.5% of the time.
  • RCE outcomes are mixed year to year. Cases with an RCE were allowed more often in 3 of the 4 measured years. Weigh the year-by-year table before spending the fee.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty37 issued · 63.3% overcome
§103 Obviousness169 issued · 55.5% overcome
§112 Definiteness & disclosure141 issued · 74.0% overcome
How applicants traverse §103 rejections🔒 Members

Of the 29 winning responses to Examiner Puttlitz's §103 rejections that Boundly has classified, 25 (86%) amended the claims and argued, and 4 argued without amending. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §103 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Puttlitz?

Draft your response with Examiner Puttlitz's record and Art Unit 1646's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response workflow.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Puttlitz.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202428.1%85.7%100.0%-14.3pp
20239.3%100.0%68.2%+31.8pp
202222.1%77.8%60.0%+17.8pp
202121.7%92.9%60.3%+32.6pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
17/818526Cyclophosphamide Analogs for Use as Immunogens and Assay Conjugates for an Immunoassay of Cyclophosphamide and IfosfamidePatented3🔒 View
18/300747Antigen-Binding Proteins and Related Methods of UsePatented1🔒 View
17/435356Transglutaminase Conjugation Method with a Glycine Based LinkerPatented2🔒 View
17/791701Muscle Targeting Complexes and Uses Thereof for Treating DystrophinopathiesAbandoned2🔒 View
See all 303 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1646 technology

ImmunologyAntibodiesAntibody-drug conjugatesBio-affecting compositionsTop CPC C07K · A61K · C12N
About this examiner. Karl J. Puttlitz examines in Art Unit 1646 (Immunology, Antibodies & Bio-Affecting Compositions, Tech Center 1600). The art unit's docket includes immunology, antibodies, antibody-drug conjugates, and bio-affecting compositions. Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Karl J. Puttlitz's allowance rate?
Examiner Puttlitz's allowance rate is 67.7%, compared with 82.4% across the USPTO and 59.9% in Art Units 1642 and 1646 for applications filed in the same years. That rate ranks Examiner Puttlitz harder than 76% of examiners.
Is Examiner Puttlitz a hard examiner?
Somewhat. Examiner Puttlitz ranks harder than 76% of examiners, in the 76th difficulty percentile (hard). Examiner Puttlitz has a 67.7% allowance rate versus 82.4% across the USPTO and 59.9% in Art Units 1642 and 1646, 1.3 office actions per application versus 1.3, and an RCE rate of 18.5% versus 20.0% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Puttlitz?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 4 measured years, by 16.7 to 50.0 percentage points. In 2021, 94.1% of decided applications with an interview were allowed, versus 45.8% of those without.
What is Examiner Puttlitz's most common rejection?
§103 obviousness, issued 169 times in the data. Applicants overcame it 55.5% of the time. Of the 29 winning responses Boundly has classified, 25 amended the claims and argued.
Is an RCE worth filing with Examiner Puttlitz?
It has varied by year, so the table is the better guide. Decided applications with an RCE were allowed more often in 3 of the 4 measured years. In 2021, 92.9% of decided applications with an RCE were allowed, versus 60.3% of those without one. In 2024, the figures were 85.7% versus 100.0%.
How long until the first office action from Examiner Puttlitz?
About 782 days on average, versus 614 days across the USPTO for applications filed in the same years.
How do I contact Examiner Karl J. Puttlitz?
Examiner Puttlitz can be reached by phone at (571) 272-0645 or by email at [email protected]. The examiner's direct line is also listed at the end of the examiner's office actions.

Put Examiner Puttlitz's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Karl J. Puttlitz, or see an error? Request a correction.